AC Immune reported biomarker results from its Phase II Vacsyn program showing biomarker shifts consistent with reduced alpha‑synuclein pathology and neuronal injury in early Parkinson’s disease. The company highlighted changes across a panel that included a‑synuclein, neurofilament light (NfL), GFAP and imaging (DaT‑SPECT) measures, and said it will seek regulatory feedback to potentially accelerate an approval pathway. External analysts noted the data are encouraging at the biomarker level but that clinical benefit remains to be demonstrated in larger, controlled readouts. AC Immune plans further discussions with regulators and to continue follow‑up.